Abstracts tagged "Systemic sclerosis"

Abstract Number: 1044 • 2019 ACR/ARP Annual Meeting
TGF-β Isoforms Modulate the RNA Cargo of Extracellular Vesicles (Exosomes) Isolated from Cultured Normal Human Lung Microvascular Endothelial Cells: A Mechanistic Link Between Endothelial Cell Dysfunction and the Establishment of a Profibrotic Phenotype in SSc?
Peter Wermuth¹ and Sergio Jimenez ¹, ¹Jefferson Institute of Molecular Medicine and Division of Connective Tissue Diseases, Thomas Jefferson University, Philadelphia, PA, Philadelphia, PA
Background/Purpose: Extracellular vesicles (EV) are a diverse assortment of lipid bilayer-bound vesicles of various sizes and origin. Exosomes are a subset of EV arising from…
Abstract Number: 1629 • 2019 ACR/ARP Annual Meeting
Significance of Abnormal Nailfold Videocapillarscopy Among Patients with Raynaud’s Phenomenon And/or Suspected Connective Tissue Disease: A Cross-Sectional Single-Center US Experience
Yasser Radwan¹, Tina Gunderson ², Cynthia Crowson ³, Alicia Hinze ¹, Kevin Moder ⁴, Floranne Ernste ⁴, Shreyasee Amin ⁴, Uma Thanarajasingam ², Thomas Osborn ¹, Kenneth Warrington ⁴, Paul Wennberg ⁴ and Ashima Makol ¹, ¹Mayo Clinic Minnesota, rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic Rochester, rochester, MN
Background/Purpose: Nailfold videocapillaroscopy (NVC) is a simple, non-invasive & highly sensitive tool to evaluate structural abnormalities of the microcirculation in vivo and considered a key…
Abstract Number: 1656 • 2019 ACR/ARP Annual Meeting
Health-Related Quality of Life in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Impact of Lung Function on Patient-Reported Outcomes in a Randomized Phase III Trial
Michael Kreuter ¹, Anna Maria Hoffmann-Vold ², Marco Matucci-Cerinic ³, Lesley Saketkoo ⁴, Kristin Highland⁵, Hilary Wilson ⁶, Margarida Alves ⁷, Nils Schoof ⁶ and Toby Maher ⁸, ¹Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Germany, Germany, Germany, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ³University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ⁴New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans; Tulane University School of Medicine, University Medical Center – Comprehensive Pulmonary Hypertension Center, USA, New Orleans, ⁵Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom
Background/Purpose: SSc-ILD is a major cause of morbidity and mortality in patients with systemic sclerosis. A subset of patients with SSc-ILD show a decline in…
Abstract Number: 2598 • 2019 ACR/ARP Annual Meeting
Different Treatment Backgrounds Do Not Influence Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon
Alberto Sulli¹, Federica Goegan ², Emanuele Gotelli ², Massimo Patane' ³, Carmen Pizzorni ³, Sabrina Paolino ³, Elisa Alessandri ⁴ and Barbara Ruaro ⁵, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Genoa, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genova, ⁵1 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Genoa, Italy
Background/Purpose: Aminaphtone treatment improves clinical symptoms of Raynaud's phenomenon (RP) and increases peripheral blood perfusion (BP) in patients with either primary or secondary RP (1-2).The…
Abstract Number: 2747 • 2019 ACR/ARP Annual Meeting
Identification of Naturally Presented Peptides of the Autoantigen Topoisomerase-I Reveals a Common Pathogenic Mechanism in Patients with Systemic Sclerosis
Eleni Tiniakou¹, Andrea Fava ², Zsuzsanna McMahan* ³, Tara Gurh ⁴, Robert O'Meally ⁴, Ami Shah ⁵, Frederick Wigley ³, Robert Cole ⁴, Francesco Boin ⁶ and Erika Darrah ¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Division of Rheumatology, Baltimore, ⁴Johns Hopkins University, Baltimore, ⁵Johns Hopkins Hospital, Baltimore, MD, ⁶UCSF, San Francisco, CA
Background/Purpose: Autoimmune responses to DNA topoisomerase-I (TOP1) are found in a subset of patients with scleroderma at high risk for interstitial lung disease (ILD) and…
Abstract Number: 389 • 2019 ACR/ARP Annual Meeting
ACR/EULAR Criteria for Myositis and Systemic Sclerosis Lack Sensitivity for Scleromyositis
Alain Meyer¹, Valérie Leclair ², Océane Landon-Cardinal ³, Benjamin Ellezam ⁴, Julie D'Aoust ⁵, Margherita Giannini ⁶, Bernard Geny ⁶, Laurent Arnaud ⁷, Jacques-Eric Gottenberg ⁸, Jean Sibilia ⁹, Minoru Satoh ¹⁰, Marvin Fritzler ¹¹, Yves Troyanov ¹² and Marie Hudson ¹³, ¹Centre de Reference des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²Division of Rheumatology, Department of Medicine, Jewish General Hospital; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Montreal, QC, Canada, ³Centre Hospitalier de l'Université de Montréal, Montréal, Canada, ⁴Department of Pathology, Centre Hospitalier Universitaire Sainte-Justine, Montréal, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶CHU de Strasbourg, Strasbourg, France, ⁷Service de Rhumatologie, Centre National de Référence des Maladies Autoimmunes Systemiques Rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, ⁸Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁹CHU Strasbourg, Strasbourg, France, ¹⁰Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹²Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹³Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Autoimmune myositis consists of a group of diseases with heterogeneous muscular and systemic manifestations. Prognosis also varies widely across the spectrum. Thus, myositis subgroups…
Abstract Number: 729 • 2019 ACR/ARP Annual Meeting
Modelled Patient Level Skin Score Trajectory Predicts Risk of Death or Major Organ-Based Complications in Diffuse Cutaneous Systemic Sclerosis
Svetlana Nihtyanova¹, Emma Derrett-Smith ¹, Carmen Fonseca ¹, Voon Ong ² and Christopher Denton ³, ¹UCL Medical School, Royal Free Campus, London, United Kingdom, ²UCL Medical School, Royal Free Campus, London, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: For most patients with diffuse cutaneous systemic sclerosis (dcSSc), skin thickness improves over time, especially with background immunosuppressive treatment. This has reduced confidence in…
Abstract Number: 1046 • 2019 ACR/ARP Annual Meeting
The Effect of Nintedanib versus Mycopheolate Mofetil in the FRA2 Mouse Model of Systemic Sclerosis Associated Interstitial Lung Disease
Thuong Trin-Minh ¹, Yun Zhang ², Jörg Distler ³ and Lutz Wollin⁴, ¹University Erlangen-Nuremberg, Erlangen-Nuremburg, Germany, ²University Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴oehringer Ingelheim, Biberach, Germany
Background/Purpose: Interstitial lung disease (ILD) is a key driver of mortality in patients with systemic sclerosis (SSc). In lack of approved treatment it constitutes a…
Abstract Number: 1630 • 2019 ACR/ARP Annual Meeting
Contribution of Chest Wall Muscle Atrophy to Decline of Forced Vital Capacity in Patients with Systemic Sclerosis-associated Interstitial Lung Disease
Takashi Nawata¹, Mikito Suzuki ², Yuichiro Shirai ³ and Masataka Kuwana ³, ¹1. Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan. 2. Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Tokyo, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Tokyo, Japan, ³Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Interstitial lung disease (ILD) is the leading causes in patients with systemic sclerosis (SSc). Forced vital capacity (FVC) is routinely used for assessment of…
Abstract Number: 1657 • 2019 ACR/ARP Annual Meeting
Sarcopenia in Systemic Sclerosis
Iván Dario Remolina Rincón¹, Maria Alak ², Graciela Alsina ³, Pedro Quevedo ², Mariano Rivero ⁴ and Damian Duartes ⁵, ¹Hospital Británico, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ²Hospital Britanico de Buenos Aires, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ³Consultorios Pampa, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Hospital Británico, Buenos Aires, Buenos Aires, Argentina, ⁵Hospital Británico, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
Background/Purpose: Gastrointestinal tract involvement in systemic sclerosis (SSc) occurs in almost all patients varying in severity and affecting motility, digestion, absorption and excretion. These abnormalities…
Abstract Number: 2599 • 2019 ACR/ARP Annual Meeting
Body Composition and Nailfold Videocapillaroscopy Patterns in a Cohort of Systemic Sclerosis Patients
Tomatis Veronica ¹, Sabrina Paolino ², Alberto Sulli³, Emanuele Gotelli ⁴, Andrea Casabella ⁵, Francesco Cattelan ⁶, Schenone Carlotta ¹, Carmen Pizzorni ², Elisa Alessandri ⁷ and Maurizio Cutolo ⁸, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genova, Liguria, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Genoa, Italy, ⁵1 Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁶Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic Hospital San Martino, University of Genoa, Genoa, Italy, ⁷Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genova, ⁸Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease, characterized by microvascular damage and progressive fibrosis. Among clinical complications, abnormal body composition and sarcopenia have been reported…
Abstract Number: 2748 • 2019 ACR/ARP Annual Meeting
Cracking a Novel Profibrotic Molecular Mechanism: lncRNA H19X and DDIT4L Crosstalk
Elena Pachera¹, Shervin Assassi ², Gloria Salazar ³, Mojca Frank-Bertoncelj ⁴, Jörg Distler ⁵, Gabriela Kania ⁶ and Oliver Distler ⁷, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Zurich, Switzerland, ²Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ³University of Texas McGovern Medical School, Houston, ⁴University Hospital Zürich, Zürich, Switzerland, ⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁶Centre of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Long noncoding RNAs (lncRNAs) are an emerging class of noncoding transcripts involved in the regulation of gene expression in health and disease. LncRNAs function…
Abstract Number: 403 • 2019 ACR/ARP Annual Meeting
Single-specificity Anti-SMN Autoantibodies Are Associated with a Novel Scleromyositis Overlap Syndrome
Alexandra Baril-Dionne ¹, Océane Landon-Cardinal², Alain Meyer ³, Josiane Bourre-Tessier ¹, Yves Troyanov ⁴, Anne-Marie Mansour ⁵, Farah Zarka ⁵, Jean-Paul Makhzoum ⁶, Jessica Nehme ⁵, Eric Rich ¹, Jean-Richard Goulet ¹, Tamara Grodzicky ¹, Isabelle Richard ⁷, Marie Hudson ⁸, Valérie Leclair ⁹, Ira Targoff ¹⁰, Minoru Satoh ¹¹, Marvin Fritzler ¹² and Jean-Luc Senecal ¹, ¹Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada, ²Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montreal, QC, Canada, ³Centre de Reference des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁴Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁵Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁶Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁷CISSS AT Rouyn-Noranda, Rouyn-Noranda, QC, Canada, ⁸Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ⁹Division of Rheumatology, Department of Medicine, Jewish General Hospital; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Montreal, QC, Canada, ¹⁰University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹²Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Autoantibodies (aAbs) to proteins comprising the survival of motor neuron (SMN) macromolecular complex have not been thoroughly studied. Only two publications described clinical associations…
Abstract Number: 731 • 2019 ACR/ARP Annual Meeting
A Systemic Review of Factors Associated with Systemic Sclerosis-associated Pulmonary Arterial Hypertension (SSc-PAH)
Yuxuan Jiang ¹, Matthew Turk ¹ and Janet Pope², ¹University of Western Ontario, London, ON, Canada, ²Western University, London, ON, Canada
Background/Purpose: Pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) is a lethal complication affecting approximately 8-15% of patients. Screening methods including echocardiography and pulmonary function…
Abstract Number: 1047 • 2019 ACR/ARP Annual Meeting
CXCL4-L1 Levels Are Elevated in Systemic Sclerosis Patients and Correlate with Pulmonary Arterial Hypertension and Capillaroscopic Indices of Vascular Damage
Vasiliki Kalliopi Bournia¹, Markos Patsouras ², Nikolaos Vlachoyiannis ³, Athanasios Tzioufas ⁴, Petros Sfikakis ⁵ and Panagiotis Vlachoyiannopoulos ⁶, ¹1st Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ²Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Greece, Athens, ³1st Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece, Athens, ⁴Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁵Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ⁶University General Hospital of Athens “Laiko”, Athens, Greece
Background/Purpose: Recent findings have implicated CXCL4 in the pathogenesis of systemic sclerosis (SSc), while also indicating a potential role of this chemokine as a biomarker…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].